Product Description
Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity.Ê (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369742/)
Mechanisms of Action: ADR Agonist,GABA Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: VIVUS
Company Location: CAMPBELL CA 95008
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Overweight|Obesity|Pediatric Obesity
Phase 3: Obesity|Type 2 Diabetes
Phase 2: Obesity|Overweight|Type 2 Diabetes|Glucose Metabolism Disorders|Sleep Apnea, Obstructive
Phase 1: Torsades de Pointes|Healthy Volunteers|Obesity